We provide regulatory-centric cGMP facility design solutions exclusively optimized for biological drug manufacturing, covering monoclonal antibodies, recombinant proteins, cell and gene therapies, vaccines and other high-value biologic products. Our design framework fully complies with FDA cGMP, EMA, EU GMP and ISO biomanufacturing standards, adopting Quality by Design (QbD) principles to embed compliance logic into every spatial and systemic layout. Different from chemical pharmaceutical plants, our solutions target the unique attributes of biological drugs, including live microbial activity, sensitive biomolecular stability and high contamination susceptibility, building audit-ready facilities that meet global biologic registration and commercialization standards.
Our design system focuses on core biomanufacturing risk control and whole-process quality assurance to address the stringent requirements of biologic production. We implement scientific functional zoning for cell bank management, upstream cell culture, downstream purification, sterile formulation and filling, and dedicated QC testing areas, achieving complete segregation of clean and dirty zones with strict pressure gradient control. Hierarchical cleanroom classification from ISO 5 to ISO 8 is precisely matched with different production stages, while specialized HVAC, purified water, process gas and waste treatment systems effectively control microbial contamination, particle concentration and cross-contamination risks, ensuring batch consistency and biological safety.
Delivering integrated full-lifecycle design services, our scope covers pre-project regulatory consultation, process-driven plant layout optimization, GMP-compliant utility system design, cleanroom structural engineering, personnel and material flow rationalization, and validation document technical support. We deeply adapt to the low-temperature, aseptic, closed and high-precision operational characteristics of biologic production processes, optimizing equipment layout, operational accessibility and pipeline routing to streamline production workflows. All architectural and mechanical designs comply with biopharmaceutical safety specifications and daily GMP management requirements, supporting stable scale-up production and experimental iteration.
Empowered by rich cross-standard biopharma engineering experience, our cGMP facility design achieves organic integration of regulatory compliance, operational efficiency and long-term scalability. We reserve flexible expansion space and intelligent monitoring interfaces in the overall scheme to accommodate future product pipeline enrichment, process upgrading and capacity expansion. Standardized cGMP design specifications minimize regulatory inspection risks and post-construction rectification costs, while refined system optimization reduces long-term operational energy consumption. We help biopharmaceutical enterprises build standardized, sustainable and globally certifiable biological drug manufacturing bases to accelerate global market layout and commercialization.
